Weaker-than-expected Bitcoin performance will enable Ethereum to outperform the top crypto and hit $40,000 by 2030, according to Standard Chartered’s latest forecastWeaker-than-expected Bitcoin performance will enable Ethereum to outperform the top crypto and hit $40,000 by 2030, according to Standard Chartered’s latest forecast

Ethereum to $40,000? Why one analyst expects the second-biggest crypto to outperform Bitcoin

Weaker-than-expected Bitcoin performance will enable Ethereum to outperform the top crypto and hit $40,000 by 2030, according to Standard Chartered’s latest forecast.

The major British multinational bank published the prediction in a research note on January 12.

“2026 will be the year of Ethereum, much like 2021 was,” Geoffrey Kendrick, Standard Chartered’s global head of digital assets research and author of the note, said.

He argues that an improvement in Ethereum’s prospects relative to Bitcoin means the price ratio between the two assets could return to its 2021 high.

At that time, the Ethereum to Bitcoin ratio hit a high of around 0.08, meaning that the price of one Ether token was 8% the value of one Bitcoin.

However in the years since, Ethereum has lagged behind, and the ratio has dropped to around 0.03.For context, if the Ethereum to Bitcoin ratio rose to around 0.16, the two crypto assets would trade at an equal market value.

Stablecoin play

Standard Chartered’s prediction highlights how traditional financial firms are growing more and more bullish on stablecoins and tokenisation — taking real world assets such as stocks, bonds or real estate, and conferring ownership of them digitally on a blockchain.

Ethereum is currently the biggest blockchain for tokenisation, hosting more than $10 billion worth of crypto and real world assets. It also hosts the majority of all stablecoins, which are often backed by US Treasury bonds.

These factors, the bank says, put Ethereum in a strong position to take advantage of the increased interest in onchain finance.

Bitcoin, on the other hand, was not designed to accommodate programmable smart contracts, and therefore has a comparatively tiny onchain ecosystem.

US Treasury Secretary Scott Bessent predicts stablecoins could grow into a $3 trillion industry by 2030. The value of all tokenised assets on blockchains could surpass $19 trillion by 2033, according to an April report from Ripple and Boston Consulting Group.

Ethereum ETFs

Onchain finance isn’t the only reason Standard Chartered sees a brighter future for Ethereum than Bitcoin.

Investment through exchange-traded funds and digital asset treasuries is less important for Ethereum’s price performance than Bitcoin’s, the bank said.

Investors have pulled over $1.9 billion out of Ethereum ETFs since November, according to DefiLlama data. In the same time, Bitcoin ETFs have seen over $4.6 billion in outflows.

Even so, while crypto ETF flows have weakened overall, “they are more constructive for ETH than for BTC at present,” Kendrick wrote.

Additionally, Ethereum developers are working on increasing the blockchain’s transaction throughput by a factor of 10 over the next two to three years. If they’re successful, this should also give Ethereum a sizable boost.

More clarity

Finally, passage of the US’ Clarity Act, a proposed crypto market structure bill, also bodes well for Ethereum and the vast onchain ecosystem it accommodates.

The bill, should it get signed into law, will provide a comprehensive regulatory framework for decentralised finance, giving traditional financial firms more confidence to integrate blockchain technology into their offerings.

Standard Chartered said it expects the clarity Act to be passed in the first quarter of 2026.

To be sure, the bank is still bullish on Bitcoin, too.

The note reiterated its Bitcoin price prediction of $500,000 by 2030, while also lowering its near-term Ethereum price targets for 2026 from $12,000 to 7,500, and from $18,000 to $15,000 for 2027.

“We expect Clarity Act passage, along with solid US equity-market performance, to push BTC to a fresh all-time high in H1, defying fears of further price declines at this stage of the Bitcoin ‘halving’ cycle,” Kendrick said.

Tim Craig is DL News’ Edinburgh-based DeFi Correspondent. Reach out with tips at tim@dlnews.com.

Market Opportunity
TOP Network Logo
TOP Network Price(TOP)
$0.000096
$0.000096$0.000096
0.00%
USD
TOP Network (TOP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23